2. Signaling Pathways
  3. Cytoskeleton
  4. Cadherin

Cadherin

Cadherins are a family of calcium-dependent cell adhesion molecules and transmembrane glycoproteins that play a crucial role in maintaining tissue architecture and cellular communication. Key members of the cadherin family include E-cadherin (CDH1), N-cadherin (CDH2), and P-cadherin (CDH3), etc. Cadherins mediate cell-cell adhesion through homophilic interactions, forming adherens junctions that connect to the actin cytoskeleton via catenins, thus influencing cellular signaling pathways related to proliferation, differentiation, and migration[1].

cadherins are involved in various signaling pathways, such as the Wnt and Notch pathways, which are critical for development and tissue homeostasis. Cadherins often bind to β-catenin (CTNNB1) through the catenin-binding domain. The catenin-binding domain of cadherin is crucial in cadherin function and it plays an important role in maintaining epithelial integrity. Dysregulation of cadherin expression is associated with several diseases, particularly cancer, such as pancreatic cancer, melanoma, hepatocellular carcinoma, glioblastoma, breast and gastric cancers. The epigenetic silencing of cadherins through mechanisms like DNA methylation further exacerbates this issue in tumor progression. Understanding cadherins' roles in cellular dynamics provides insights into potential therapeutic targets for cancer and other diseases characterized by altered cell adhesion[1].

Cadherin Related Products (26):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13541
    ADH-1
    		Antagonist 99.93%
    ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
    ADH-1
  • HY-P99053
    Tralokinumab
    		99.12%
    Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.
    Tralokinumab
  • HY-160623
    Rentosertib
    		Modulator 99.96%
    Rentosertib (INS018 055) (compound 112) is the orally active TNIK and MAP4K4 inhibitor with IC50 values of 12-120, 12-120 nM, respectively.
    Rentosertib
  • HY-13541A
    ADH-1 trifluoroacetate
    		Antagonist 99.74%
    ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.
    ADH-1 trifluoroacetate
  • HY-N2232
    N-​Feruloyloctopamine
    		Inducer 99.91%
    N-Feruloyloctopamine (N-trans-Feruloyloctopamine) is an antioxidant component that can be isolated from garlic skin. N-Feruloyloctopamine can inhibit tumor cell proliferation and invasion, and induce apoptosis. N-Feruloyloctopamine has antitumor activity and can be used in the research of tumors such as hepatocellular carcinoma.
    N-​Feruloyloctopamine
  • HY-P991728
    Zarutatug
    		Inhibitor
    Zarutatug is an anti-CDH17 (cadherin 17) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Zarutatug
  • HY-175236
    SF-9-2
    SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research.
    SF-9-2
  • HY-175257
    Theophylline-platinum(IV) prodrug-1
    		Inhibitor
    Theophylline-platinum(IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer.
    Theophylline-platinum(IV) prodrug-1
  • HY-P990363
    Anti-CDH17/Cadherin-17 Antibody (PTA001_A4)
    		Inhibitor 99.28%
    The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CDH17/Cadherin-17 Antibody (PTA001_A4)
  • HY-149894
    MC-1-F2
    		Inhibitor 99.78%
    MC-1-F2 is a FOXC2 inhibitor. MC-1-F2 shows a binding affinity (Kd) of 26 μM for full-length FOXC2. MC-1-F2 reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. MC-1-F2 can be used for the study of CRPC and breast cancer.
    MC-1-F2
  • HY-153607
    HDAC-IN-55
    		98.40%
    HDAC-IN-55(8j) is a small molecular compound that can increase the expression of E-cadherin and inhibit the proliferation of cancer cells.
    HDAC-IN-55
  • HY-N2013
    Aristolactam I
    		Activator 99.31%
    Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
    Aristolactam I
  • HY-164712
    E-Cadherin activator-1
    		Activator 99.01%
    E-cadherin activator-1 (Compound 13m) is an E-Cadherin activator. E-cadherin activator-1 can be used in the study of colorectal carcinoma.
    E-Cadherin activator-1
  • HY-N10926
    (+)-Glaucarubinone
    		Inducer
    (+)-Glaucarubinone is a quassinoid compound and a potent activator protein-1 (AP-1) inhibitor with an EC50 value of 0.13 µM. (+)-Glaucarubinone has anti-tumor activity and can be used in the research of tumors such as hepatocellular carcinoma.
    (+)-Glaucarubinone
  • HY-P990645
    PF-03732010
    		99.68%
    PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    PF-03732010
  • HY-P991100
    Anti-CDH17/Cadherin-17 Antibody (10C12)
    		Inhibitor 99.29%
    Anti-CDH17/Cadherin-17 Antibody (10C12) is a human antibody expressed in CHO cells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CDH17/Cadherin-17 Antibody (10C12)
  • HY-P990248
    Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1)
    		Inhibitor
    Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonal antibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma.
    Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1)
  • HY-145268
    SLEC-11
    		Inhibitor
    SLEC-11 is a CDH1/E-cadherin modulator that potently inhibits cell death in E-cadherin-deficient cells (EC50=8.2 μM). SLEC-11 can be used to study potential synthetic lethal therapies for gastric cancer.
    SLEC-11
  • HY-174247
    CPS-021
    CPS-021 is a selective PAK4 PROTAC degrader with a DC50 of 50 nM. CPS-021 has potent antimigratory and invasive activity and significantly suppresses the invasion and metastasis of tumor cells in A549-luc lung metastasis mice model. Pink: PAK4 ligand (HY-174822); Blue: CRBN ligase ligand (HY-10984); Black: linker
    CPS-021
  • HY-145269
    AL-GDa62
    		Inhibitor
    AL-GDa62 is a derivative of the CDH1/E-cadherin modulator SLEC-11 (HY-145268) and induces apoptosis in CDH1-/- cells. AL-GDa62 has an EC50 of 3.2 μM and 2 μM for isogenic mammary epithelial cells MCF10A-WT (wild type) and mutant MCF10A-CDH1-/-, respectively. AL-GDa62 specifically inhibits TCOF1, ARPC5, and UBC9, and suppresses SUMOylation at low micromolar concentrations.
    AL-GDa62